NAV
$41.83
AUM
$176.1M
Expense Ratio
-
Dividend Yield
0.00%
Beta
0.00
Currency
USD
| YTD | 1M | 3M | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|
| +19.83% | +14.21% | +12.74% | +65.03% | - | - |
| # | Symbol | Name | Weight |
|---|---|---|---|
| 1 | RVMD | Revolution Medicines Inc Ordinary Shares | 7.73% |
| 2 | LLY | Eli Lilly and Co | 4.82% |
| 3 | RHHBY | Roche Holding AG ADR | 4.21% |
| 4 | COGT | Cogent Biosciences Inc | 4.10% |
| 5 | NOVN.SW | Novartis AG Registered Shares | 4.03% |
| 6 | IMNM | Immunome Inc Ordinary Shares | 3.91% |
| 7 | CELC | Celcuity Inc | 3.58% |
| 8 | MRK | Merck & Co Inc | 3.57% |
| 9 | AZN.L | AstraZeneca PLC | 3.54% |
| 10 | NUVL | Nuvalent Inc Class A | 3.37% |
Under normal circumstances, the fund seeks to achieve its investment objective by investing at least 80% of its net assets, which include borrowings for investment purposes, in publicly listed companies that derive at least 50% of revenues from oncology. The fund is non-diversified.
Inception Date: 2023-08-14